Segal, N. H. (2018). Phase I Study of Single-Agent Utomilumab (PF-05082566), a 4-1BB/CD137 Agonist, in Patients with Advanced Cancer. The American Association for Cancer Research (AACR).
Chicago Style (17th ed.) CitationSegal, N. H. Phase I Study of Single-Agent Utomilumab (PF-05082566), a 4-1BB/CD137 Agonist, in Patients with Advanced Cancer. The American Association for Cancer Research (AACR), 2018.
MLA (9th ed.) CitationSegal, N. H. Phase I Study of Single-Agent Utomilumab (PF-05082566), a 4-1BB/CD137 Agonist, in Patients with Advanced Cancer. The American Association for Cancer Research (AACR), 2018.
Warning: These citations may not always be 100% accurate.